BioCardia (NASDAQ:BCDA) Announces Earnings Results

Posted by Brenda Bartman on May 15th, 2026

BioCardia (NASDAQ:BCDA – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04), FiscalAI reports.

Here are the key takeaways from BioCardia’s conference call:

BioCardia said the CardiAMP heart failure data showed compelling benefits versus control, including reduced adverse remodeling and a statistically significant composite outcome in a high-risk biomarker subgroup.
The company reported that Japan’s PMDA is inclined to accept the trial data as the basis for a regulatory submission and initial approval, and BioCardia is preparing a Shonin application over the next ~7 months.
BioCardia said the FDA found the safety profile acceptable and discussed a pre-market approval pathway, while encouraging completion of the ongoing CardiAMP Heart Failure II study to support the filing.
For its Helix delivery system, FDA indicated no safety or compatibility concerns and suggested potential approval paths, including aligning it with CardiAMP or pursuing a standalone de novo route.
First-quarter 2026 expenses fell year over year to $2.3 million, with net loss improving to $2.3 million, but cash and cash equivalents ended at only $951,000, underscoring the company’s need for additional funding.

BioCardia Stock Performance

Shares of BCDA traded down $0.08 during trading hours on Friday, hitting $1.01. The company had a trading volume of 311,625 shares, compared to its average volume of 126,912. The stock has a market capitalization of $11.05 million, a price-to-earnings ratio of -0.78 and a beta of 0.56. The firm has a fifty day moving average price of $1.18 and a 200-day moving average price of $1.26. BioCardia has a 52-week low of $1.00 and a 52-week high of $2.49.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a research report on Monday, April 20th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $25.00.

Check Out Our Latest Analysis on BCDA

Institutional Trading of BioCardia

A number of institutional investors and hedge funds have recently bought and sold shares of BCDA. Cetera Investment Advisers purchased a new position in BioCardia in the second quarter worth about $40,000. DRW Securities LLC purchased a new stake in shares of BioCardia during the fourth quarter valued at approximately $72,000. Finally, Geode Capital Management LLC increased its position in shares of BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after acquiring an additional 27,263 shares in the last quarter. 20.57% of the stock is currently owned by institutional investors.

BioCardia Company Profile

(Get Free Report)

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.